A detailed history of Advisor Partners Ii, LLC transactions in Genmab A/S stock. As of the latest transaction made, Advisor Partners Ii, LLC holds 11,074 shares of GMAB stock, worth $228,013. This represents 0.02% of its overall portfolio holdings.

Number of Shares
11,074
Previous 9,550 15.96%
Holding current value
$228,013
Previous $362,000 7.73%
% of portfolio
0.02%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 26, 2023

BUY
$35.27 - $42.24 $53,751 - $64,373
1,524 Added 15.96%
11,074 $390,000
Q2 2023

Aug 10, 2023

BUY
$37.4 - $42.94 $21,729 - $24,948
581 Added 6.48%
9,550 $362,000
Q1 2023

May 15, 2023

BUY
$34.88 - $43.22 $1,988 - $2,463
57 Added 0.64%
8,969 $338,000
Q4 2022

Feb 14, 2023

BUY
$33.8 - $47.06 $81,052 - $112,849
2,398 Added 36.81%
8,912 $377,000
Q3 2022

Nov 14, 2022

BUY
$31.52 - $373.61 $205,321 - $2.43 Million
6,514 New
6,514 $209,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Advisor Partners Ii, LLC Portfolio

Follow Advisor Partners Ii, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Partners Ii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisor Partners Ii, LLC with notifications on news.